Novo Nordisk partners with OpenAI to accelerate drug discovery

Novo Nordisk has recently announced a strategic partnership with OpenAI, positioning the Danish pharmaceutical giant at the intersection of artificial intelligence and healthcare innovation. The collaboration spans research and development, manufacturing, supply chain and commercial operations, with full integration targeted by the end of 2026.

At its core, the partnership aims to do something the industry has long aspired to but rarely achieved at scale: meaningfully compress the time between scientific discovery and patient access. OpenAI’s capabilities will be applied to analyse complex biological and clinical datasets, surface promising drug candidates, and accelerate the hypothesis-testing that underpins early-stage pharmaceutical research.

Mike Doustdar, president and CEO of Novo Nordisk, framed the partnership in terms of the patients waiting on the other side of discovery. “There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” he said. “Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.”

For investors, the scope of the deal extends well beyond the laboratory. OpenAI will also work with Novo Nordisk to improve efficiency across manufacturing, supply chain, distribution and corporate operations, areas where marginal gains at the scale Novo operates can translate into significant financial impact. A workforce upskilling programme is also included, with OpenAI supporting AI literacy across the company’s global employee base.

Sam Altman, CEO of OpenAI, described the collaboration as an opportunity to demonstrate what AI can deliver in life sciences specifically. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care,” he said.

The partnership has been structured with data protection protocols, governance frameworks and human oversight built in from the outset, an increasingly important consideration as regulators and the public scrutinise AI use in healthcare settings.

Pilot programmes are already being launched across research and development, manufacturing and commercial operations ahead of the full integration deadline.

The deal adds to a growing list of pharmaceutical companies aligning themselves with leading AI platforms, but the Novo Nordisk move stands out for its breadth. Rather than a narrow research collaboration, this is a company-wide transformation programme backed by one of the most prominent names in artificial intelligence.

---

---

Related Topics and Keywords

AIinHealthcare, Diabetes, Novo Nordisk, openAI, Wegovy®